Can medical products be developed on a non-profit basis? Exploring product development partnerships for neglected diseases

Science and Public Policy

Volumn 42, Issue 3, 2015, Pages 315-338

  Munoz V ^a   Visentin, F ^a   Foray, D ^a   Gaule P ^b  

^a EPFL   (Switzerland)

^b CERGE EI   (Czech Republic)

Author keywords

Innovation; Neglected diseases; Non profit; R D collaboration

Indexed keywords

DEVELOPING WORLD; DISEASE TREATMENT; DRUG DEVELOPMENT; INNOVATION; NONPROFIT ORGANIZATION; PARTNERSHIP APPROACH; PUBLIC HEALTH; PUBLIC-PRIVATE PARTNERSHIP; RESEARCH AND DEVELOPMENT; WELFARE PROVISION;

EID: 84930829270     PISSN: 03023427     EISSN: None     Source Type: Journal    
DOI: 10.1093/scipol/scu049     Document Type: Article

References (61)

1. Årdal, C. and Røttingen, J. A. (2012) 'Open source drug discovery in practice: A case study', PLoS Neglected Tropical Diseases, 6/9: e1827.
2. Bio Ventures for Global Health. (2012) Developing New Drugs and Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape. San Francisco, CA: Bio Ventures for Global Health.
3. Boston Consulting Group. (2010) PathVaccineProductDevelopment Assessment: Summary of Findings, accessed 5 Aug 2014.
4. Brooks, A. D., Wells, W. A., McLean, T. D., Khanna, W. A. et al. (2010) 'Ensuring that developing countries have access to new healthcare products: The role of product development partnerships', Innovation Strategy Today, 3: 1-5.
5. Cernuschi, T., Furrer, E., Schwalbe, N., Jones, A. et al. (2011) 'Advance market commitment for pneumococcal vaccines: Putting theory into practice', Bulletin of the World Health Organization, 89: 913-8.
6. Chataway, J., Brusoni, S., Cacciatori, E., Hanin, R. et al. (2007) 'The International AIDS Vaccine Initiative (IAVI) in a changing landscape of vaccine development: A public-private partnership as knowledge broker and integrator', European Journal of Development Research, 19: 100-17.
7. Chataway, J., Hanlin, R., Mugwagwa, J. and Muraguri, J. (2010) 'Global health social technologies: Reflections on evolving theories and landscapes', Research Policy, 39: 1277-88.
8. Coase, R. (1960) 'The problem of social cost,', Journal of Law and Economics, 3: 1-44.
9. Cockburn, I. (2005), 'Blurred boundaries: Tensions between open scientific resources and commercial exploitation of knowledge in biomedical research'. Paper prepared for the Advancing Knowledge and the Knowledge Economy Conference, held 10-11 January 2005, National Academy of Sciences, Washington, DC.
10. Cockburn, I. (2006) 'Is the pharmaceutical industry in a productivity crisis?' In: Lerner, J. and Stern, S. (eds) Innovation Policy and the Economy, Vol. 7, pp. 1-32. Cambridge, MA: MIT Press.
11. Cockburn, I. and Henderson, R. (2001) 'Scale and scope in drug development: Unpacking the advantages of size in pharmaceutical research', Journal of Health Economics, 20: 1033-57.
12. Cohen, W. (2010) 'Fifty years of empirical studies of innovative activity and performance'. In: Hall, B.H. and Rosenberg, H. (eds) Handbook of the Economics of Innovation, Vol. 1, pp. 129-98. Elsevier B.V.
13. DiMasi, J., Hansen, R. and Grabowski, H. (2003) 'The price of innovation: New estimates of drug development costs', Journal of Health Economics, 22: 151-85.
14. Drugs for Neglected Diseases Initiative and Médecins Sans Frontières. (2012) Medical Innovation for Neglected Patients, accessed 24 Jun 2013.
15. Ekins, S., Waller, C., Bradley, M., Clark, A. and Williams, A. (2013) 'Four disruptive strategies for removing drug discovery bottlenecks', Drug Discovery Today, 18: 265-71.
16. Grace, C. (2006) Developing New Technologies to Address Neglected Diseases: The Role of Product Development Partnerships and Advanced Market Commitments. London: DFID Health Resource Centre.
17. Grace, C. (2010) Product Development Partnerships (PDPs): Lessons from PDPs Established to Develop New Health T echnologies for Neglected Diseases. London: DFID Human Development Resource Centre.
18. Guedj, I. and Scharfstein, D. (2004) 'Organizational scope and investment: Evidence from the drug development strategies and performance of biopharmaceutical firms', NBER Working Papers, 10933. Cambridge, MA: National Bureau of Economic Research.
19. Hegde, D. and Sampat, B. N. (2014) 'Can private money buy public science? Disease group lobbying and federal funding for biomedical research', Forthcoming in Management Science. Available at SSRN: accessed 24 Jun 2013.
20. Henderson, R. and Cockburn, I. (1996) 'Scale, scope, and spillovers: The determinants of research productivity in drug discovery', RAND Journal of Economics, 27: 32-59.
21. Hobday, M., Davies, A. and Prencipe, A. (2005) 'Systems integration: A core capability of the modern corporation', Industrial and Corporate Change, 14: 1109-43.
22. International Federation of Pharmaceutical Manufacturers and Associations (2012) Status Report on Pharmaceutical R&D to Address Diseases that Disproportionately Affect People in Low and Middle Income Developing Countries accessed 24 Jun 2013.
23. Juliano, R. L. (2013) 'Pharmaceutical innovation and public policy: The case for a new strategy for drug discovery and development', Science and Public Policy, 40: 393-405.
24. Kremer, M. (2001) 'Creating markets for new vaccines-Part I: Rationale'. In: Jaffe, A., Lerner, J. and Stern, S. (eds) Innovation Policy and the Economy, pp. 35-72. Cambridge, MA: MIT Press.
25. Levine, R., Kremer, M. and Albright, A. (2005) Making Markets for Vaccines: Ideas to Action. Report of the Center for Global Development Advance Market Commitment Working Group. Washington, DC: Center for Global Development.
26. Light, D. and Lexchin, J. (2012) 'Pharmaceutical research and development: What do we get for all that money?', BMJ, 345: e4348.
27. Light, D. and Warburton, R. (2011) 'Demythologizing the high costs of pharmaceutical research', BioSocieties, 6: 34-50.
28. Moran, M. (2005a) 'A breakthrough in R&D for neglected diseases: New ways to get the drugs we need', PLoS Medicine, 2/9: e302.
29. Moran, M. (2005b) The New Landscape of Neglected Disease Drug Development. London: LSE and Wellcome Trust.
30. Moran, M., Guzman, J., Ropars, A. L. and Illmer, A. (2010) 'The role of product development partnership in research and development for neglected diseases', International Health, 2: 114-22.
31. Médecins Sans Frontières. (2001) Fatal Imbalance: The Crisis in Research and Development for Drugs for Neglected Diseases, accessed 24 Oct 2012.
32. Médecins Sans Frontières. (2013) Global Vaccines Community Must Bring Price of New Vaccines Down, accessed 5 Aug 2014.
33. Medicines Malaria Venture. (2012) Fact Sheet: The RTS,S Malaria Vaccine Candidate, accessed 4 Aug 2014.
34. Morel, C., Acharya, T., Broun, D., Dangi, A. et al. (2005) 'Health innovation networks to help developing countries address neglected diseases', Science, 309/5733: 401-4.
35. Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C. and Greyson, D. (2011) 'The cost of drug development: A systematic review', Health Policy, 100: 4-17.
36. Munos, B. (2009) 'Lessons from 60 years of drug discovery', Nature Reviews Drug Discovery, 8: 959-68.
37. Muñoz, V. (2014), 'Intellectual property management in nonprofit medical product development partnerships' (unpublished manuscript).
38. Nelson, R. B. (1959) 'The simple economics of basic scientific research', The Journal of Political Economy, 67/3, pp 297-306.
39. Papaioannou, T., Wield, D. and Chataway, J. (2009) 'Knowledge ecologies and ecosystems? An empirically grounded reflection on recent developments in innovation systems theory', Environment and Planning C: Government and Policy, 27: 319-39.
40. Payne, D., Gwynn, M., Holmes, D. and Pompliano, D. (2007) 'Drugs for bad bugs: Confronting the challenges of antibacterial discovery', Nature Reviews Drug Discovery, 6: 29-40.
41. Pedrique, B., Strub-Wourgaft, N., Some, C., Olliaro, P. et al. (2013) 'The drug and vaccine landscape for neglected diseases (2000-11): A systematic assessment', The Lancet Global Health, 1/6: e371-9, accessed 28 Oct 2013.
42. Policy Cures. (2012) G-FINDER: Global Funding of Innovation for Neglected Diseases, Report for 2012. Sydney, NSW: Australia: Policy Cures.
43. Ridley, R. (2001) 'Putting the partnership into public-private partnerships', Bulletin of the World Health Organization, 79: 694-7.
44. Ridley, R. (2004), 'Product development public private partnerships for diseases of poverty: Are there more efficient alternatives? Are there limitations?'. Paper presented at Initiative on Public-Private Partnership for Health Meeting, held 15-6 April 2004, London.
45. Røttingen, J. A., Regmi, S., Eide, M., Young, A. et al. (2013) 'Mapping of available health research and development data: What's there, what's missing, and what role is there for a global observatory?', The Lancet, 382/9900: 1286-307.
46. Schubert, C. (2009) 'Steve Reed', Nature Biotechnology, 27/11: 971-2.
47. Schuhmacher, A., Germann, P., Trill, H. and Gassmann, O. (2013) 'Models for open innovation in the pharmaceutical industry', Drug Discovery Today, 18: 23-4.
48. Scudellari, M. (2011) 'Are advance market commitments for drugs a real advance?', Nature Medicine, 17: 139.
49. So, A. and Ruiz-Esparza, Q. (2012) 'Technology innovation for infectious diseases in the developing world', Infectious Diseases of Poverty, 1/2: 1-9.
50. Sridhar, D. (2012) 'Who sets the global health research agenda? The challenge of multi-bifinancing', PLoS Med, 9/9: e1001312.
51. Teece, D. (2012) 'Dynamic capabilities: Routines versus entrepreneurial action', Journal of Management Studies, 49: 1395-401.
52. Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J. et al. (2002) 'Drug development for neglected diseases: A deficient market and a public health policy failure', The Lancet, 359: 2188-94.
53. Toole, A. (2012) 'The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry', Research Policy, 41: 1-12.
54. UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. (2007) Making a Difference: 30 Years of Research and Capacity Building in Tropical Diseases. Geneva: World Health Organization.
55. Webber, D. and Kremer, M. (2001) 'Perspectives on stimulating industrial research and development for neglected infectious diseases', Bulletin of the World Health Organization, 79: 735-41.
56. Weder, R. and Grubel, H. (1993) 'The new growth theory and coasean economics: Institutions to capture externalities', Review of World Economics (Weltwirtschaftliches Archiv), Springer, 129/3: 488-513.
57. Wells, S., Diap, G. and Kiechel, J. (2013) 'The story of artesunate-mefloquine (ASMQ), innovative partnerships in drug development: Case study', Malaria Journal, 12: 68.
58. World Health Organization. (2006) Public Health-Innovation and Intellectual Property Rights: Report of the Commission on Intellectual Property Rights, Innovation and Public Health. Geneva: World Health Organization.
59. World Health Organization. (2010) First WHO Report on Neglected Tropical Diseases: Working to Overcome the Global Impact of Neglected Tropical Diseases. Geneva: World Health Organization.
60. World Health Organization. (2012a) The Evolving Threat of Microbial Resistance, Options for Action. Geneva: World Health Organization.
61. World Health Organization. (2012b) Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination. Report of the Consultative Expert Working Group on Research and Development: Finance and Coordination, accessed 5 Aug 2014.